Sun Pharma reported strong revenue and profit growth in the March quarter, but EBITDA margins faced pressure from increased investments and lower milestone income. The company anticipates range-bound margins and moderating revenue growth in FY27, driven by specialty launches and R&D spending. Domestic formulations remain robust, while US segment recovery is expected to be gradual.
Market Samachar is a news aggregator. This article was originally published by Stocks-Markets-Economic Times. Tap the button above to read the full story on their site.
Trade NSE stocks with virtual coins. Build a portfolio, climb the leaderboard — zero real money.
1,500+ Indian market quiz questions. Earn coins per correct answer, climb leagues, build streaks.
Live gainers · losers · FII/DII · MTF · News Buzz. The complete Indian market dashboard.
Swipe BULL or BEAR on today's news. Earn +5 coins per swipe, +20 bonus when you're right.